Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 4, 2014, Pages 649-658

  Reiner, Caecilia S ^a   Stolzmann, Paul ^a,b   Husmann, Lars ^b   Burger, Irene A ^b   Hüllner, Martin W ^b   Schaefer, Niklaus G ^b   Schneider, Paul M ^b   Von Schulthess, Gustav K ^b   Veit Haibach, Patrick ^a,b  

^a University Hospital Zurich Institut fur Diagnostische Radiologie   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Hepatology; Liver metastasis; Multimodality imaging; Oncology; PET CT; PET MRI

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; HEMIHEPATECTOMY; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; AGED; CLINICAL PROTOCOL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION STUDY; GASTROINTESTINAL TUMOR; LIVER NEOPLASMS; MULTIMODAL IMAGING; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SECONDARY;

AGED; CLINICAL PROTOCOLS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897909481     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2654-x     Document Type: Article

References (31)

1. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007;356:1545-59. (Pubitemid 46588419)
2. Kennedy TJ, Cassera MA, Khajanchee YS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal livermetastases: 10-year experience. J Surg Oncol. 2013;107:324-8.
3. Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18:3657-65.
4. Malik HZ, Hamady ZZ, Adair R, Finch R, Al-Mukhtar A, Toogood GJ, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33:468-73. (Pubitemid 46586090)
5. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698-708; discussion 708-10.
6. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507. (Pubitemid 43200300)
7. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027-34; discussion 1035-6.
8. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepaticmetastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-47; discussion 47-50.
9. Valls C, Andia E, Sanchez A, Guma A, Figueras J, Torras J, et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology. 2001;218:55-60. (Pubitemid 32151272)
10. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010;257:674-84.
11. Scharitzer M, Ba-Ssalamah A, Ringl H, Kolblinger C, Grunberger T, Weber M, et al. Preoperative evaluation of colorectal livermetastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol. 2013;23:2187-96.
12. Donati OF, Hany TF, Reiner CS, von Schulthess GK, Marincek B, Seifert B, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/ CTand Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51:692-9.
13. Yong TW, Yuan ZZ, Jun Z, Lin Z, He WZ, Juanqi Z. Sensitivity of PET/MR images in livermetastases fromcolorectal carcinoma. Hell J Nucl Med. 2011;14:264-8.
14. Rappeport ED, Loft A, Berthelsen AK, von der Recke P, Larsen PN, Mogensen AM, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol. 2007;48:369-78. (Pubitemid 46633866)
15. Hardie AD, Naik M, Hecht EM, Chandarana H, Mannelli L, Babb JS, et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol. 2010;20:1431-41.
16. Mannelli L, Bhargava P, Osman SF, Raz E, Moshiri M, Laffi G, et al. Diffusion-weighted imaging of the liver: a comprehensive review. Curr Probl Diagn Radiol. 2013;42:77-83.
17. Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging. 2007;7:2-9. (Pubitemid 47528076)
18. Couinaud C. Leading principles for controlled hepatectomies (author's transl). Chirurgie. 1980;106:136-42. (Pubitemid 10104023)
19. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50S.
20. Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, Babb JS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology. 2008;246:812-22.
21. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology. 2005;237:123-31. (Pubitemid 41346155)
22. Park SH, Moon WK, Cho N, Chang JM, Im SA, Park IA, et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol. 2012;22:18-25.
23. Hamm B, Mahfouz AE, Taupitz M, Mitchell DG, Nelson R, Halpern E, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology. 1997;202:677-82. (Pubitemid 27093436)
24. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224:748-56. (Pubitemid 34919808)
25. Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez- Moller A, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-55.
26. Quick HH, von Gall C, Zeilinger M, Wiesmuller M, Braun H, Ziegler S, et al. Integrated whole-body PET/MR hybrid imaging: clinical experience. Invest Radiol. 2013;48:280-9.
27. Martinez-Moller A, Eiber M, Nekolla SG, Souvatzoglou M, Drzezga A, Ziegler S, et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med. 2012;53:1415-26.
28. Catana C, van der Kouwe A, Benner T, Michel CJ, Hamm M, Fenchel M, et al. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med. 2010;51:1431-8.
29. Martinez-Moller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd'hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-6.
30. Eiber M, Martinez-Moller A, Souvatzoglou M, Holzapfel K, Pickhard A, Loffelbein D, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38:1691-701.
31. Dirisamer A, Halpern BS, Schima W, Heinisch M, Wolf F, Beheshti M, et al. Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol. 2008;10:335-40.